Ratings SNDL Inc.

Equities

SNDL

CA83307B1013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2 ^USD	-3.38%		+9.29%	+21.95%

Apr. 02	Cannabis Stocks Rise Pre-Bell After Florida Supreme Court Allows Ballot Initiative to Legalize Marijuana	MT
Apr. 02	Pot producers climb as recreational cannabis to go on Florida ballot	RE

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SNDL INC.	+21.95%	545M	D+
ELI LILLY AND COMPANY	+25.61%	672B	C+
NOVO NORDISK A/S	+25.87%	570B	B
JOHNSON & JOHNSON	-5.24%	360B	C+
MERCK & CO., INC.	+16.49%	321B	B-
ABBVIE INC.	+8.28%	300B	C+
ASTRAZENECA PLC	+7.09%	217B	B+
ROCHE HOLDING AG	-9.12%	204B	A+
NOVARTIS AG	+5.01%	199B	B-
PFIZER, INC.	-8.75%	149B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes